Get the Stockscreener App
20.33
4.69%
-1.00
Apellis Pharmaceuticals Inc stock is traded at $20.33, with a volume of 5.58M.
It is down -4.69% in the last 24 hours and down -19.42% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$21.33
Open:
$21.29
24h Volume:
5.58M
Relative Volume:
2.06
Market Cap:
$2.57B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-10.01
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-23.25%
1M Performance:
-19.42%
6M Performance:
+2.11%
1Y Performance:
-26.58%
1-Day Range:
$20.03
$21.29
1-Week Range:
$20.03
$27.46
52-Week Range:
$16.10
$31.17
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
20.33 | 2.70B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 5.8% on Analyst Downgrade - MarketBeat
Apellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say - sharewise.com
Rising SYFOVRE Demand and Prefilled Syringe Plan Could Be A Game Changer For Apellis Pharmaceuticals (APLS) - Yahoo Finance
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
APLS: Cantor Fitzgerald Lowers Price Target, Maintains Overweigh - GuruFocus
Cantor Fitzgerald Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $35.00 - MarketBeat
Forecasting The Future: 9 Analyst Projections For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $28.00 by Analysts at Needham & Company LLC - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Apellis stock, lowers price target - Investing.com UK
Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
APLS: Needham Maintains Buy Rating, Lowers Price Target to $28 | - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Strong 2025 Revenue Update And Nephrology Expansion - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Analysis: A 50% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Apellis Pharmaceuticals Reports Preliminary 2025 Financial Results and Strategic Updates - TradingView — Track All Markets
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownHere's What Happened - MarketBeat
Apellis Pharmaceuticals Details Syfovre Growth, Prefilled Syringe Filing at JPM Healthcare Conference - MarketBeat
Apellis (APLS) stock slides 15% after $689 mln 2025 revenue preview at JPM conference - TechStock²
Goldman Sachs reiterates Sell rating on Apellis stock amid revenue miss - Investing.com Canada
Apellis (APLS) Shares Plummet Over 17% - GuruFocus
Apellis Pharmaceuticals Reports Preliminary 2025 Revenues of $689 Million, Highlights Growth in SYFOVRE and EMPAVELI Sales - Quiver Quantitative
Apellis Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
Why (APLS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE? - simplywall.st
Aug Breakouts: Is Apellis Pharmaceuticals Inc. stock near bottom after declineMarket Performance Recap & Daily Price Action Insights - ulpravda.ru
Can Apellis Pharmaceuticals Inc. stock sustain institutional interest2025 Investor Takeaways & AI Powered Buy/Sell Recommendations - ulpravda.ru
Can Apellis Pharmaceuticals Inc. (1JK) stock surprise with quarterly resultsJuly 2025 Weekly Recap & Risk Managed Investment Strategies - Улправда
Will Apellis Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - Улправда
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersBlue Chip Stock Analysis & Superior Wealth Strategies - bollywoodhelpline.com
How buybacks impact Apellis Pharmaceuticals Inc. stock value2025 Buyback Activity & Smart Swing Trading Techniques - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekers - ulpravda.ru
Apellis Pharmaceuticals (NASDAQ:APLS) Trading 7.8% HigherWhat's Next? - MarketBeat
Apellis stock jumps nearly 8% as investors look to JPM healthcare update - TechStock²
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Navigating a 40.73% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
Resistance Check: Is Apellis Pharmaceuticals Inc stock cheap at current valuation2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn
Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN
Understanding Momentum Shifts in (APLS) - Stock Traders Daily
Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛
Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда
Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда
Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN
APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):